They also found higher incidence of AF, left atrial enlargement, fibrosis, and elevated CaMK2 in ibrutinib-treated mice compared with wild type, that was not replicated in a BTK knock out mouse model or mice treated with a more specific BTK inhibitor, acalabrutinib. This evidence concerns the gene BTK and atrial fibrillation.